2025-12-25 - Analysis Report
Okay, here's a comprehensive analysis of Tempus AI (TEM) based on the data provided.

**1) Return Rate Comparison & Company Overview**

*   **Company Overview:** Tempus AI Inc. is a technology company focusing on precision medicine through data analysis and AI.
*   **TEM Cumulative Return:** 15.06%
*   **VOO (S&P 500) Cumulative Return:** 30.11%
*   **Divergence:** -15.0.  This means TEM underperformed the S&P 500 by 15.0 percentage points over the measured period.
*   **Relative Divergence:** 22.3. This indicates the current divergence (-15.0) is positioned at the bottom 22.3% of the stock's divergence fluctuation range, based on its historical max and min divergences.  This suggests the underperformance compared to the S&P 500 is closer to the worst historical divergence than to the best.

**Alpha, Beta Analysis:**

| Year       | CAGR  | MDD   | Alpha  | Beta | Cap(B) |
|------------|-------|-------|--------|------|--------|
| 2023-2025  | 15.0% | 76.7% | -14.0% | 0.3  | 11.4   |

*   **CAGR (Compound Annual Growth Rate):**  15.0%.  Indicates the average annual growth rate of the investment over the period.
*   **MDD (Maximum Drawdown):** 76.7%. This is very high, suggesting significant volatility and potential risk of large losses.
*   **Alpha:** -14.0%.  Indicates TEM underperformed its benchmark (likely the S&P 500, but not explicitly stated) on a risk-adjusted basis. A negative alpha means the investment yielded less return than expected given its risk.
*   **Beta:** 0.3. This indicates that TEM is less volatile than the market. For every 1% move in the market, TEM is expected to move 0.3%.
*   **Cap(B):** 11.4. This represents the company's market capitalization in billions of dollars.

**2) Recent Stock Price Fluctuations**

*   **Current Close:** 64.46
*   **Last Market Data:** Price 64.26, Previous Close 64.72, Change -0.71
*   **5-day SMA:** 65.61
*   **20-day SMA:** 72.86
*   **60-day SMA:** 80.13

The Simple Moving Averages (SMAs) show a clear downward trend: the 5-day SMA is below the 20-day SMA, which is below the 60-day SMA. The last market change also suggests a recent decrease. The current close price is lower than all three SMA values. This indicates bearish momentum in the short, medium, and long term.

**3) Indicator Analysis**

*   **Market Risk Indicator (MRI):** 0.8 (Medium Investment). Suggests a moderate level of risk.
*   **RSI (Relative Strength Index):** 23.89. This is significantly below 30, indicating that the stock is oversold.  This *could* signal a potential buying opportunity if the stock is fundamentally sound.
*   **PPO (Percentage Price Oscillator):** -1.42. A negative PPO suggests that the shorter-term moving average is below the longer-term moving average, confirming the downtrend seen in the SMA analysis.
*   **Hybrid Signal:** cash_0%_Buy 100% of cash (14 shares - Very Safe - MRI:0.90) Monthly invest 5.0% of total investment ($1,000.00) (Cash Ratio: 0% on 2025-12-01). This suggests the algorithm recommends using all available cash to buy TEM. It labels this as "Very Safe" and recommends a 5% monthly investment. The MRI of 0.90 associated with this signal is slightly higher than the overall market risk indicator.
*   **Recent (20 days) relative divergence change:** -9.7 (단기하락).  This confirms a recent short-term decline.
*   **Expected Return (%):** NaN. No expected return data is provided. This is crucial for long-term investment decisions and needs to be investigated to gain understanding of what long term returns will look like from here.
*   **Fluctuation note:** The small change between the closing price and the previous day's closing price (-0.71) suggests no significant, immediate rebound or decline.

**4) Recent News & Significant Events**

*   **Omeros Stock Pops On Yartemlea Approval:** This is unrelated to TEM, so it shouldn't influence the analysis.
*   **Tempus AI (TEM): Assessing Valuation After a Recent Share Price Pullback:** This article is directly relevant. It suggests a recent decline in the share price, prompting an evaluation of the company's valuation. This ties into the SMA and indicator analysis.
*   **Tempus AI, Inc. Stock (TEM) Opinions on FDA Clearance and Recent Price Drop:** Indicates opinions surrounding the stock and recent FDA events (likely catalysts for change).
*   **Insider Selling: Tempus AI (NASDAQ:TEM) CEO Sells 166,250 Shares of Stock:** This is a negative signal. Insider selling, especially by the CEO, can raise concerns about the company's future prospects.
*   **Tempus AI Approaching Profitability Despite GAAP Losses:** This is a positive signal, indicating that the company is moving towards financial sustainability.
*   **JPMorgan Lowers Tempus AI (TEM) PT to $80, Maintains Neutral Rating:** This suggests that while JPMorgan sees some potential in TEM, they are not strongly bullish. Lowering the price target may indicate concerns about the company's growth prospects or the overall market environment.

**4-2) Analyst Opinions**

*   **Consensus:** Buy (Mean of 2.14).  Overall, analysts have a positive outlook.
*   **Target Price:** Average $88.92, High $105.00, Low $80.00.  This suggests a potential upside from the current price, but the range is wide.
*   **Recent Rating Changes:** No recent changes are provided, so no implications can be drawn.

**5) Comprehensive Analysis**

Tempus AI (TEM) is currently facing challenges. The stock is underperforming the S&P 500, exhibits high volatility (MDD of 76.7%), and is in a downtrend based on the SMA analysis. The RSI indicates that the stock may be oversold. Recent news includes an assessment of valuation after a share price pullback, opinions on FDA clearance and recent price drop, CEO insider selling, reports of approaching profitability, and JPMorgan lowering their price target.

The insider selling is a significant cause for concern. While analysts maintain a "Buy" consensus and see potential upside, the lowered price target and the lack of concrete expected return data suggest caution is warranted. The recent news articles highlighting price pullbacks and valuation assessments reinforce the need for careful consideration. The positive note about approaching profitability is encouraging, but needs to be balanced against the risks.

**In summary, while the "Hybrid Signal" suggests buying, a more conservative approach is advisable. Further research into the reason for insider selling, a deeper understanding of the "Expected Return," and a clear plan for achieving profitability are crucial before making a significant investment.**


**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.